GlassScriptPhysician profile
Brittian W Beaver
NPI 1740241892
$5,360.60
in general payments reported to CMS, 2019-2025
35 companies · $532 in 2025
The $532 reported for 2025 was more than what 82% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $372 · 2020: $566 · 2021: $860 · 2022: $1,002 · 2023: $1,037 · 2024: $993 · 2025: $532.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,362 · Education: $199.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,362.38 |
| Education | $198.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $932.78 | 2019-2025 | Lo Loestrin Fe, Ubrelvy, Qulipta |
| Exeltis, USA INC. | $699.44 | 2020-2025 | Slynd, Tyblume, Nuvessa |
| Astellas Pharma US INC | $486.34 | 2023-2025 | Veozah |
| Pfizer INC. | $440.12 | 2019-2025 | |
| Novo Nordisk INC | $236.60 | 2021-2025 | Wegovy, Saxenda |
| Exact Sciences Corporation | $226.91 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Mayne Pharma Commercial LLC | $219.15 | 2021-2024 | |
| Avion Pharmaceuticals | $216.66 | 2019-2023 | Balcoltra |
| Hologic Sales and Service, LLC | $186.56 | 2019-2023 | Coolseal Generator, Acessa Provu System |
| Idorsia Pharmaceuticals US INC | $182.90 | 2022-2024 | Quviviq |
| Daiichi Sankyo INC. | $181.60 | 2019-2023 | Injectafer |
| Therapeuticsmd, INC. | $176.76 | 2019-2022 | |
| Mylan Pharmaceuticals INC. | $140.32 | 2019-2022 | |
| Mission Pharmacal Company | $117.00 | 2020-2022 | |
| Acella Pharmaceuticals, LLC | $98.27 | 2021-2025 | NP Thyroid 60 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $87.52 | 2022-2025 | Nexplanon |
| Merck Sharp & Dohme LLC | $78.83 | 2019-2022 | |
| Lupin INC. | $72.85 | 2019-2020 | |
| Aspira Women'S Health INC | $71.79 | 2020-2022 | |
| Azurity Pharmaceuticals, INC. | $67.54 | 2023 | Adthyza |
| Shield Therapeutics INC | $59.08 | 2023-2024 | Accrufer |
| Amag Pharmaceuticals, INC. | $49.19 | 2019 | |
| Channel Medsystems, INC. | $44.39 | 2022 | |
| Myovant Sciences INC. | $40.40 | 2021-2022 | |
| Axsome Therapeutics, INC. | $35.56 | 2025 | Symbravo |
| Millicent US INC | $31.84 | 2025 | Intrarosa, Femlyv |
| Eisai INC. | $28.15 | 2020-2021 | |
| Abbott Laboratories | $23.35 | 2019 | |
| Scynexis, INC. | $22.33 | 2022 | |
| Mycovia Pharmaceuticals, INC. | $20.60 | 2023 | Vivjoa |
| Trevena, INC. | $18.94 | 2021 | |
| Ibsa Pharma INC. | $18.24 | 2020 | |
| Allergan, INC. | $16.83 | 2019 | |
| Agile Therapeutics, INC. | $16.57 | 2022 | |
| Medicem INC. | $15.19 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brittian Beaver listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.